Literature DB >> 23793188

Hidradenitis suppurativa: retrospective study of 20 cases.

Nurimar Conceição Fernandes1, Camilla Pimentel A Franco, Cíntia Maria O Lima.   

Abstract

In this study, twenty cases of severe hidradenitis suppurativa are reported, mainly in non-white people and in axillary areas. Wide surgical excision has offered good results, although relapses have occurred at variable intervals in the follow-up period.

Entities:  

Mesh:

Year:  2013        PMID: 23793188      PMCID: PMC3754392          DOI: 10.1590/abd1806-4841.20131637

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


Hidradenitis suppurativa is a suppurative and chronic disease, located mainly in areas with apocrine glands, which affects adults of both genders with no racial predisposition. Genetic predisposition and hormonal influence are described, but its pathogenesis is not precisely known.[1,2] An observational retrospective study (1978 to 2010) was conducted in a dermatology ward. The study included nine men (four white/ five non-white) and eleven women (three white/ eight non-white) aged 30 to 49 years in half the cases. The locations included the axillary area (five cases); inguinal and axillary regions (four); gluteal and perineal/ perianal areas (four); axillary, gluteal, perineal, and inguinal regions (five); gluteal and perineal areas (two cases). Alcoholism and smoking were detected in eight cases, obesity in seven, and smoking in five. All cases were biopsied and showed a chronic suppurative inflammatory pattern, as well as epithelioid cell granulomas and foreign-body giant cells. The reason for admission was a formal surgical indication in all cases due to gravity, long duration of the disease (from months to 20 years), clinical status, degree of skin involvement, complications of the disease, and clinical treatment failure (topical and systemic antibiotics, intralesional corticoids, oral isotretinoin).[3,4,5] Surgery consisted of excision of the affected area and repair with grafts and skin flaps. Routinely, 14 days before surgery, patients were administered oral prednisone at a dose of 40mg/day (without weaning later), enabling the surgeon to better handle the injuries by reducing the inflammatory component. Although there was visible improvement in quality of life, all patients relapsed at varying intervals (1-2 years). In a patient with dilated cardiomyopathy, for whom extensive surgery was contraindicated (buttocks and inner thighs), radiation therapy successfully controlled the disease. In an HIV-positive patient, surgery (inguinal, perineal, and gluteal areas) was rejected. Radiotherapy was initiated as an alternative therapy, but in the eighth session the patient progressed to a genital herpes infection. Radiotherapy was stopped and acyclovir was started. It was considered an appropriate option, since biological therapy showed minimal evidence of clinically significant efficacy.[6,7] The efficacy of radiotherapy in the treatment of hidradenitis suppurativa has been evaluated in 231 patients, with total doses between 3.0 and 8.0 Gy. In chronic and recurrent cases, two or more series with a total dose of 10.0 Gy were administered.[8] In 40 percent of cases, there was improvement of symptoms; in 38 percent of cases, there was complete relief of symptoms. Only two patients did not respond to therapy.[8] The conclusions of the present study are: (1) clinical treatment in the early stages of the disease produces transient results; (2) the radical excision of tissues, including the apocrine glands, is the definitive treatment, and (3) in cases of long evolution, surgical treatment does not prevent recurrence.[1-5]
  8 in total

Review 1.  Hidradenitis suppurativa: pathogenesis and management.

Authors:  D E M Slade; B W Powell; P S Mortimer
Journal:  Br J Plast Surg       Date:  2003-07

Review 2.  Contemporary surgical treatment of hidradenitis suppurativa (HS) with a focus on the use of the diode hair laser in a case.

Authors:  Virendra N Sehgal; Prashant Verma; Satish Sawant; Munish Paul
Journal:  J Cosmet Laser Ther       Date:  2011-06-29       Impact factor: 2.247

Review 3.  Chronic hidradenitis suppurativa in the inguinal, perineal and scrotal regions. A case report and review of the literature.

Authors:  Daniele Pironi; Francesco Caruso; Alessandra Panarese; Maurizio Vendettuoli; Domenico Mascagni; Lorenzo Moraldi; Angelo Filippini
Journal:  Ann Ital Chir       Date:  2010 Nov-Dec       Impact factor: 0.766

4.  [Radiotherapy of hidradenitis suppurativa--still valid today?].

Authors:  D Fröhlich; D Baaske; M Glatzel
Journal:  Strahlenther Onkol       Date:  2000-06       Impact factor: 3.621

5.  [Hidradenitis suppurativa treated with infliximab].

Authors:  Daniel Lago Obadia; Egon Luiz Rodrigues Daxbacher; Thiago Jeunon; Alexandre Carlos Gripp
Journal:  An Bras Dermatol       Date:  2009 Nov-Dec       Impact factor: 1.896

6.  A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa.

Authors:  Robert A Lee; Erica Dommasch; James Treat; Joslyn Sciacca-Kirby; Samuel Chachkin; Jennifer Williams; Daniel B Shin; James J Leyden; Carmela Vittorio; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2009-01-31       Impact factor: 11.527

7.  Surgical management of hidradenitis suppurativa.

Authors:  Adnan Menderes; Ozgur Sunay; Haluk Vayvada; Mustafa Yilmaz
Journal:  Int J Med Sci       Date:  2010-07-19       Impact factor: 3.738

8.  Hidradenitis suppurativa.

Authors:  J Revuz
Journal:  J Eur Acad Dermatol Venereol       Date:  2009-09       Impact factor: 6.166

  8 in total
  2 in total

Review 1.  [Surgical treatment options for hidradenitis suppurativa/acne inversa].

Authors:  L Scholl; S Hessam; S Reitenbach; F G Bechara
Journal:  Hautarzt       Date:  2018-02       Impact factor: 0.751

Review 2.  [Hidradenitis suppurativa /acne inversa-surgical options, reconstruction and combinations with drug therapies-an update].

Authors:  P Cramer; S Schneider-Burrus; M Kovács; L Scholl; M Podda; F G Bechara
Journal:  Hautarzt       Date:  2021-07-06       Impact factor: 0.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.